Satellos Bioscience Inc. ownership update: Qiming U.S. Healthcare Fund III, L.P. reports beneficial ownership of 1,725,247 common shares as of March 31, 2026, representing 8.3% of the class. The filing states 20,831,190 Shares outstanding as of March 27, 2026.
The report identifies Qiming U.S. Healthcare GP III, LLC as the general partner and names Mark McDade and Gary Rieschel as managing partners who may be deemed to beneficially own the same shares through shared voting and dispositive power.
Positive
None.
Negative
None.
Insights
Large passive stake disclosure by Qiming group with shared control attribution.
The filing reports 1,725,247 shares owned by Qiming U.S. Healthcare Fund III, L.P., equal to 8.3% of outstanding common shares as of the stated dates. Ownership is held directly by the fund with shared voting and dispositive power attributed to affiliated entities and individuals.
Disclosure clarifies the chain of control: Qiming GP is the general partner and Mark McDade and Gary Rieschel are managing partners. The report is a standard beneficial ownership statement; subsequent filings would show any material changes.
Key Figures
Shares beneficially owned:1,725,247 sharesPercent of class:8.3%Shares outstanding:20,831,190 Shares+1 more
4 metrics
Shares beneficially owned1,725,247 sharesBeneficial ownership as of March 31, 2026
Percent of class8.3%Based on 20,831,190 Shares outstanding as of March 27, 2026
Shares outstanding20,831,190 SharesOutstanding shares reported as of March 27, 2026
Shared voting power1,725,247 sharesShared voting power reported on cover page as of March 31, 2026
Key Terms
Schedule 13G, beneficially owned, shared dispositive power
3 terms
Schedule 13Gregulatory
"Row headings and form type reference indicate Schedule 13G filing"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially ownedregulatory
"Item 4(a) states the aggregate number of common shares "beneficially owned" by such Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive powerfinancial
"Cover page values show "Shared Dispositive Power 1,725,247.00""
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Satellos Bioscience Inc.
(Name of Issuer)
Common Shares, no par value
(Title of Class of Securities)
80401L803
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
80401L803
1
Names of Reporting Persons
Qiming U.S. Healthcare Fund III, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,725,247.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,725,247.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,725,247.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.3 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
80401L803
1
Names of Reporting Persons
Qiming U.S. Healthcare GP III, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,725,247.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,725,247.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,725,247.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
80401L803
1
Names of Reporting Persons
Mark McDade
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,725,247.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,725,247.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,725,247.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.3 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
80401L803
1
Names of Reporting Persons
GARY E RIESCHEL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,725,247.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,725,247.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,725,247.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.3 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Satellos Bioscience Inc.
(b)
Address of issuer's principal executive offices:
ROYAL BANK PLAZA, S. TOWER, 200 BAY ST. SUITE 2800, Toronto, A6, M5J 2J3.
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
Qiming U.S. Healthcare Fund III, L.P. ("Qiming")
Qiming U.S. Healthcare GP III, LLC ("Qiming GP")
Mark McDade ("McDade")
Gary Rieschel ("Reischel")
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)
Address or principal business office or, if none, residence:
Qiming U.S.
11100 NE 8th Street, Suite 200
Bellevue, WA 98004
(c)
Citizenship:
Qiming Delaware
Qiming GP Delaware
McDade United States
Rieschel United States
(d)
Title of class of securities:
Common Shares, no par value
(e)
CUSIP Number(s):
80401L803
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of common shares (the "Shares") of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
The Reporting Persons' ownership of the Shares consists of 1,725,247 shares directly held by Qiming.
Qiming GP is the general partner of Qiming. McDade and Rieschel are the managing partners of Qiming GP. Each of Qiming GP, McDade and Rieschel may be deemed to beneficially own the shares owned by Qiming
(b)
Percent of class:
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the Shares beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 20,831,190 Shares outstanding as of March 27, 2026, as reported in the Issuer's Annual Report on Form 40-F filed with the Securities and Exchange Commission (the "SEC") on March 27, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Qiming U.S. Healthcare Fund III, L.P.
Signature:
/s/ Mark McDade
Name/Title:
By Qiming U.S. Healthcare GP III, LLC, its general partner, By Mark McDade, Managing Partner
What stake does Qiming (MSLE) report in Satellos Bioscience?
Qiming reports beneficial ownership of 1,725,247 common shares of Satellos as of March 31, 2026. That holding represents 8.3% of the 20,831,190 shares outstanding reported as of March 27, 2026.
Who within the Qiming group is attributed with the Satellos shares?
The shares are directly held by Qiming U.S. Healthcare Fund III, L.P.. Qiming U.S. Healthcare GP III, LLC is the general partner; Mark McDade and Gary Rieschel are managing partners and may be deemed beneficial owners through shared power.
What voting and dispositive powers are disclosed for the reported shares?
The filing shows 0 sole voting and dispositive power and 1,725,247 shared voting and dispositive power for each Reporting Person as of March 31, 2026, indicating shared control within the Qiming group structure.
What is the filing type and why was it submitted?
This is a Schedule 13G beneficial ownership filing for Satellos Bioscience. It discloses ownership and control details for holders of significant passive positions and explains relationships among affiliated reporting persons.
What share totals and dates anchor the percentage calculation?
The 8.3% figure is calculated using 20,831,190 Shares outstanding reported in the Issuer's Annual Report on March 27, 2026. The beneficial ownership count is as of March 31, 2026.
